期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替格瑞洛对ST段抬高型急性冠脉综合征合并糖尿病患者的心肌保护作用 被引量：16

下载PDF
导出
摘要 目的评价替格瑞洛对ST段抬高型急性冠脉综合征合并糖尿病患者的心肌保护作用。方法选择ST段抬高型急性冠脉综合征合并糖尿病患者157例,随机分为对照组(78例)和观察组(79例)。在经皮冠脉介入治疗(PCI)和常规治疗基础上,对照组给予氯吡格雷,观察组给予替格瑞洛,维持治疗6个月。比较两组患者血清肌酸激酶同工酶(CK-MB)和心肌肌钙蛋白(c Tn I)水平,左心室舒张末内径(LVDD)、左心室射血分数(LVEF)等功能指标,以及主要不良心血管事件(MACE)的发生率和治疗期间出血等不良反应。结果治疗前两组患者的基线资料差异无统计学意义。PCI术后24 h,两组患者的CK-MB、c Tn I水平差异无统计学意义但维持在较高水平;术后72 h,两项指标逐渐降低,且观察组显著低于对照组。PCI术后1周和6个月,两组患者的血小板聚集率(ADP)、心脏功能指标LVEF和LVDD较治疗前有显著改善(P<0.05),且观察组显著低于对照组。PCI术后6个月,观察组不良心血管事件显著低于对照组(P<0.05)。治疗期间,除观察组呼吸困难患者高于对照组外,其他不良反应的发生率差异无统计学意义。结论对于糖尿病合并ST段抬高型急性冠脉综合征患者,替格瑞洛能有效地改善心肌损伤,降低不良心血管事件发生率,且不增加出血风险。
作者 李晓云 董颀 陈敏生
机构地区 广州医科大学附属第二医院心内科
出处 《广东医学》 CAS 北大核心 2015年第8期1257-1260,共4页 Guangdong Medical Journal
关键词 替格瑞洛 ST段抬高型急性冠脉综合征 糖尿病 心肌保护
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献15

  • 1HU D Y, PAN C Y, YU J M. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey[J]. Eur Heart J, 2006, 27 (21) : 2573 -2579. 被引量：1
  • 2中国心脏调查组,胡大一,潘长玉.中国住院冠心病患者糖代谢异常研究——中国心脏调查[J].中华内分泌代谢杂志,2006,22(1):7-10. 被引量：470
  • 3LENZEN M, RYDENL L, OHRVIK J, et al. Diabetes known or newly detected, but not impaired glucose regulation, has a nega- tive influence on 1 -year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart [ J ]. Eur Heart J, 2006, 27 (24) : 2969 - 2974. 被引量：1
  • 4叶永刚,蒋利,徐颖杰,岳静雯,朱频.糖代谢异常对急性冠脉综合征患者远期预后的影响[J].中国临床医学,2013,20(3):289-291. 被引量：8
  • 5ASTRAZENECA BRILINTA, Brilique(ticagrelor) [ EB/OL]. ht- tp://www, astrazenneca, com/Medicines/Cardiovascular/Product/ Brilinta - Brilique, 2013 -01 - 10. 被引量：1
  • 6WARTAK S A, LOTFI A, ROTHBERG M. Ticagrelor versus clo-pidogrel in acute coronary syndromes [ J ]. N Engl J Med, 2009, 361 (24) : 2386 -2387. 被引量：1
  • 7YANG W, LU J, WENG J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12) : 1090 - 1101. 被引量：1
  • 8RADKE P W, SCHUNKERT H. Diabetics with acute coronary syndrome : advances, challenges, and uncertainties [J]. Eur Heart J, 2010, 31(24): 2971 -2973. 被引量：1
  • 9STOREY R F. Pharmacology and clinical trials of reversibly bind- ing P2Y12 inhibitors[J]. Thromb Haemost, 2011, 105 Suppl 1: S75 - S81. 被引量：1
  • 10JAMES S, ANGIOLILO D J, COMEL J H, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes : a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial[J]. Eur Heart J, 2010, 31(24) : 3006 -3016. 被引量：1

二级参考文献31

  • 1蒋利,沈卫峰,张建盛,魏盟.糖尿病患者冠状动脉内支架术后的远期疗效[J].中华内科杂志,2004,43(6):433-435. 被引量：5
  • 2李素青,田玉华,朱敏,杨超元.中老年糖尿病流行病学调查方法探讨[J].实用老年医学,1996,10(4):175-176. 被引量：13
  • 3King H,Aubert RE,Herman WH.Global burden of diabetes 1995-2025.Prevalence,numerical estimates and projections.Diabetes Care,1998,21:1414-1431. 被引量：1
  • 4Bartnik M,Malmberg K,Hamsten A,et al.Abnormal glucose tolerance-a common risk factor in patients with acute myocardial infarction in comparison with population-based controls.J Int Med,2004,256:288-297. 被引量：1
  • 5Coutinho M,Gerstein HC,Wang Y,et al.The relationship between glucose and incident cardiovascular events:a metaregression analysis of published data from 20 studies of 95 783 individuals followed for 12.4years.Diabetes Care,1999,22:233-240. 被引量：1
  • 6The DECODE study group on behalf of the European Diabetes Epidemiology Group.Glucose tolerance and cardiovascular mortality.Arch Int Med,2001,161:397-404. 被引量：1
  • 7Bartnik M,Malmberg K,Norhammar A,et al.Newly detected abnormal glucose tolerance:an important predictor of long-term outcome after myocardial infarction.Eur Heart J,2004,25:1990-1997. 被引量：1
  • 8Norhammar A,Tenerz A,Nilsson G,et al.Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus:a prospective study.Lancet,2002,359:2140-2144. 被引量：1
  • 9Bartnik M,Ryden L,Ferrari R,et al.The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe:the Euro Heart Survey on diabetes and the heart.Eur Heart J,2004,25:1880-1890. 被引量：1
  • 10Hashimoto K,Ikewaki K,Yagi H,et al.Glucose intolerance is common in Japanese patients with acute coronary syndrome who were not previously diagnosed with diabetes.Diabetes Care,2005,28:1182-1186. 被引量：1

共引文献483

同被引文献180

  • 1柳晓娜,朱宁,魏国峰,王纪文,李忠艳.糖尿病合并急性冠状动脉综合征患者血小板表面PAC-1和CD62P表达水平[J].中国动脉硬化杂志,2015,23(2):161-164. 被引量：16
  • 2LOTRIONTE M, BONDI-ZOCCAI GC, AGOSTONI P, et oi. Meta- analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention[J]. Am J Cardiol, 2007, 100(8): 1199-1206. 被引量：1
  • 3HARRINGTON RA, STONE GW, MCNULTY S, et al. Platelet inhibition with cangrelor in patients undergoing PCI[J]. N Engl J Med, 2009, 361(24): 2318-2329. 被引量：1
  • 4JAMES S, ANGIOLILLO DJ, CORNEL JH, et 01. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes(PLATO) trial[J]. Eur Heart J, 2010, 31 (24) : 3006- 3016. 被引量：1
  • 5TAYLOR J. Third universal definition of myocardial infarction[J]. Eur Heart J, 2012, 33(20) : 2506-2507. 被引量：1
  • 6STEG PG, HUBER K, ANDREOTYI F, et ol. Bleeding in acute coronary syndromes and percutaneous coronary intervention : position paper by the Working Group on Thrombosis of the European Society of Cardiology[J]. Eur Heart J, 2011, 32 (15) : 1854-1864. 被引量：1
  • 7WIVIOTI" SD, ANTMAN EM, GIBSON CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38(TRITONTIMI38)[J]. Am Heart J, 2006, 152(4): 627-635. 被引量：1
  • 8FRERE C, CUISSET T, GABORIT B, et ol. The CYP2C19"17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome[J]. J Thromb Haemost, 2009, 7(8): 1409-1411. 被引量：1
  • 9NYLANDER S, FEMIA EA, SCAVONE M, et ol. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism[J]. J Thromb Heamost, 2013, 11 (10) : 1867- 1876. 被引量：1
  • 10GURBEL PA, BLIDEN KP, BUTLER K, et al. Randomized double- blind assessment of the ONSET and OFFSET of the antiplatelet effects of tieagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study [J]. Circulation, 2009, 120(25): 2577-2585. 被引量：1

引证文献16

二级引证文献126

广东医学
2015年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部